Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMB6ADI)

• Drug Name: Delta12-PGJ2 Drug Info
• Synonyms: Dddd-PGD2; delta(12)-PGJ2; delta-12-prostaglandin D2

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

• Cross-matching ID:
  PubChem CID: 5280885
  ChEBI ID: CHEBI:28130
  CAS Number: CAS 87893-54-7
  TTD Drug ID: DMB6ADI

Molecule-Related Drug Atlas

Drug(s) Targeting Prostaglandin D2 receptor 2 (PTGDR2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
LAROPIPRANT	DM5FABJ	Coronary heart disease	BA80.Z	Phase 4	[5]
Setipiprant	DMZ61IA	Asthma	CA23	Phase 3	[6]
Fevipiprant	DM4NX0C	Asthma	CA23	Phase 3	[7]
Ramatroban	DMB8UQ3	Perennial allergic rhinitis	CA08.03	Phase 2/3	[8]
AMG 853	DM973N4	Asthma	CA23	Phase 2	[9]
ADC-3680	DM8GHIX	Allergic rhinitis	CA08.0	Phase 2	[10]
ARRY-502	DM17469	Allergic asthma	CA23.0	Phase 2	[11]
QAV-680	DMIZYV1	Allergic rhinitis	CA08.0	Phase 2	[12]
AP-761	DMISQOZ	Asthma	CA23	Phase 2	[13]
AZD1981	DMMCL9F	Chronic obstructive pulmonary disease	CA22	Phase 2	[14]

Drug(s) Targeting Prostaglandin D2 receptor (PTGDR)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
LAROPIPRANT	DM5FABJ	Coronary heart disease	BA80.Z	Phase 4	[5]
Setipiprant	DMZ61IA	Asthma	CA23	Phase 3	[15]
QAW-039	DMPCFXN	Asthma	CA23	Phase 3	[16]
AMG 853	DM973N4	Asthma	CA23	Phase 2	[9]
ONO-4053	DMX4MVP	Allergic rhinitis	CA08.0	Phase 2	[17]
TS-022	DMMNXIW	Atopic dermatitis	EA80	Phase 2	[18]
S-555739	DMXDVNZ	Allergy	4A80-4A85	Phase 2	[19]
MK-1029	DM8ZTW7	Asthma	CA23	Phase 2	[10]
SAR-389644	DMA6O9R	Allergic rhinitis	CA08.0	Phase 1	[20]
192C86	DMQ8NTZ	Thrombosis	DB61-GB90	Phase 1	[21]

Drug(s) Affected By Histone acetyltransferase p300 (EP300)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Quercetin	DM3NC4M	Obesity	5B81	Approved	[22]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[23]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[24]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[25]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[26]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[27]
Menthol	DMG2KW7	Back pain	ME84.Z	Approved	[28]
Enzalutamide	DMGL19D	Prostate cancer	2C82.0	Approved	[29]
Niclosamide	DMJAGXQ	Cestodes infection	1F70-1F76	Approved	[30]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[31]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Prostaglandin D2 receptor (PTGDR)	TTNVEIR	PD2R_HUMAN	Agonist	[2]
Prostaglandin D2 receptor 2 (PTGDR2)	TTQDMX5	PD2R2_HUMAN	Agonist	[3]

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
Histone acetyltransferase p300 (EP300)	OTL8QJDX	EP300_HUMAN	Gene/Protein Processing	[4]

References

• [1] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 1876).
• [2] Characterization of the recombinant human prostanoid DP receptor and identification of L-644,698, a novel selective DP agonist. Br J Pharmacol. 1998 Apr;123(7):1317-24.
• [3] Molecular pharmacology of the human prostaglandin D2 receptor, CRTH2. Br J Pharmacol. 2002 Dec;137(8):1163-72.
• [4] Targeting of histone acetyltransferase p300 by cyclopentenone prostaglandin (12)-PGJ(2) through covalent binding to Cys(1438). Chem Res Toxicol. 2012 Feb 20;25(2):337-47. doi: 10.1021/tx200383c. Epub 2011 Dec 16.
• [5] Discovery of a potent and selective prostaglandin D2 receptor antagonist, [(3R)-4-(4-chloro-benzyl)-7-fluoro-5-(methylsulfonyl)-1,2,3,4-tetrahydroc... J Med Chem. 2007 Feb 22;50(4):794-806.
• [6] Setipiprant, a selective CRTH2 antagonist, reduces allergen-induced airway responses in allergic asthmatics. Clin Exp Allergy. 2014 Aug;44(8):1044-52.
• [7] Fevipiprant in the treatment of asthma. Expert Opin Investig Drugs. 2018 Feb;27(2):199-207.
• [8] CRTH2-specific binding characteristics of [3H]ramatroban and its effects on PGD2-, 15-deoxy-Delta12, 14-PGJ2- and indomethacin-induced agonist resp... Eur J Pharmacol. 2005 Nov 7;524(1-3):30-7.
• [9] Safety and efficacy of the prostaglandin D2 receptor antagonist AMG 853 in asthmatic patients.J Allergy Clin Immunol.2013 Feb;131(2):339-45.
• [10] Update on the status of DP2 receptor antagonists; from proof of concept through clinical failures to promising new drugs. Expert Opin Investig Drugs. 2014 Jan;23(1):55-66.
• [11] Clinical pipeline report, company report or official report of Array BioPharma (Drug: ARRY-502).
• [12] Discovery and characterization of NVP-QAV680, a potent and selective CRTh2 receptor antagonist suitable for clinical testing in allergic diseases. Bioorg Med Chem. 2013 Nov 1;21(21):6582-91.
• [13] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800028464)
• [14] Clinical pipeline report, company report or official report of AstraZeneca (2009).
• [15] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [16] Effect Of QAW039, An Oral Prostaglandin D2 Receptor (DP2/CRTh2) Antagonist, Upon Sputum And Bronchial Eosinophilic Inflammation And Clinical Outcomes In Treatment-Resistant Asthma: A Phase 2a Randomized Placebo-Controlled Trial. American Thoracic Society Journals. 2015.
• [17] Effect of ONO-4053, a DP1 (prostaglandin D2 receptor) Antagonist, on Prostaglandin D2-Induced Nasal Congestion. Journal of Allergy and Clinical Immunology Volume 135, Issue 2, Supplement, February 2015, Pages AB219.
• [18] Effects of TS-022, a newly developed prostanoid DP1 receptor agonist, on experimental pruritus, cutaneous barrier disruptions and atopic dermatitis... Eur J Pharmacol. 2007 Feb 5;556(1-3):207-14.
• [19] Clinical pipeline report, company report or official report of Shionogi (2011).
• [20] US patent application no. 2008,0300,217, Combination therapy with fumaric acid esters for the treatment of autoimmune and,or inflammatory disorders.
• [21] Prostanoid receptor antagonists: development strategies and therapeutic applications. Br J Pharmacol. 2009 September; 158(1): 104-145.
• [22] Suppression of transforming growth factor beta/smad signaling in keloid-derived fibroblasts by quercetin: implications for the treatment of excessive scars. J Trauma. 2004 Nov;57(5):1032-7. doi: 10.1097/01.ta.0000114087.46566.eb.
• [23] Histone Acetyltransferase p300/CREB-binding Protein-associated Factor (PCAF) Is Required for All-trans-retinoic Acid-induced Granulocytic Differentiation in Leukemia Cells. J Biol Chem. 2017 Feb 17;292(7):2815-2829. doi: 10.1074/jbc.M116.745398. Epub 2017 Jan 4.
• [24] Essential role of cell cycle regulatory genes p21 and p27 expression in inhibition of breast cancer cells by arsenic trioxide. Med Oncol. 2011 Dec;28(4):1225-54.
• [25] THC exposure of human iPSC neurons impacts genes associated with neuropsychiatric disorders. Transl Psychiatry. 2018 Apr 25;8(1):89. doi: 10.1038/s41398-018-0137-3.
• [26] Nuclear and Mitochondrial DNA Methylation Patterns Induced by Valproic Acid in Human Hepatocytes. Chem Res Toxicol. 2017 Oct 16;30(10):1847-1854. doi: 10.1021/acs.chemrestox.7b00171. Epub 2017 Sep 13.
• [27] Quantitative proteomics reveals a broad-spectrum antiviral property of ivermectin, benefiting for COVID-19 treatment. J Cell Physiol. 2021 Apr;236(4):2959-2975. doi: 10.1002/jcp.30055. Epub 2020 Sep 22.
• [28] Repurposing L-menthol for systems medicine and cancer therapeutics? L-menthol induces apoptosis through caspase 10 and by suppressing HSP90. OMICS. 2016 Jan;20(1):53-64.
• [29] NOTCH signaling is activated in and contributes to resistance in enzalutamide-resistant prostate cancer cells. J Biol Chem. 2019 May 24;294(21):8543-8554. doi: 10.1074/jbc.RA118.006983. Epub 2019 Apr 2.
• [30] Growth inhibition of ovarian tumor-initiating cells by niclosamide. Mol Cancer Ther. 2012 Aug;11(8):1703-12.
• [31] Physiological and toxicological transcriptome changes in HepG2 cells exposed to copper. Physiol Genomics. 2009 Aug 7;38(3):386-401.